Skip to content

Study comparing the effectiveness of Drakshadi and Shigruadi eye drops with Haridra Khanda in allergic conjunctivitis

Comparative evaluation of the efficacy of Drakshadi eye drops and Shigruadi eye drops with Haridra Khanda in Vataja Abhishyanda (simple allergic conjunctivitis): An open-label, double-arm randomized controlled clinical trial - NILL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/111774
Enrollment
60
Registered
2026-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H108- Other conjunctivitis

Interventions

None listed

Sponsors

KM Purnima
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients presenting signs and symptoms of Abhishyanda (simple allergic conjunctivitis, vernal keratoconjunctivitis). 2.Between the age group of 16-50 years. 3.Patients willing for trial and follow up.

Exclusion criteria

Exclusion criteria: 1.Patients having viral and bacterial conjunctivitis. 2.Patients suffering from Atopic keratoconjunctivitis, Giant papillary conjunctivitis. 3.Patients having complicated eye diseases and trachoma, chalazion, stye, pterygium, dacryocystitis, trichiasis etc. 4.Patients suffering from corneal opacity, ulcers. 5.Patients suffering from major systemic illness necessitating long term treatment.

Design outcomes

Primary

MeasureTime frame
Improvement in the symptoms of Vataja Abhishyanda (Allergic Conjunctivitis)i.e .Kandu(itching),Achchahasruta( watery discharge).Timepoint: Assessment on 0th day, 15th day and 30th day, Treatment period- 30 days Follow up- 30 days Total duration of trial including follow up 60 days Window period 3 days

Secondary

MeasureTime frame
1. Improvement in the associated symptoms of Vataja Abhishyanda like Stambana, Shirobhitapa, Alpshophta, Parushya and Sangharsha. 2. Improvement in the Absolute eosinophil count and IgE . 3. Improvement in conjunctival smear test. 4. Improvement in the reduction of papillae, follicles, congestion in conjunctiva and chemosis examined through slit lamp biomicroscopy. Timepoint: Assessment on 0th day, 15th day and 30th day, Treatment period- 30 days Follow up- 30 days Total duration of trial including follow up 60 days Window period 3 days

Countries

India

Contacts

Public ContactDR KM Purnima

All India Institute of Ayurveda, New Delhi

pankajkundal1146@gmail.com7291887810

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026